News & Views
Structural Data Platform to help Advance Treatments for Brain Disease
Sep 07 2019
Pharma company Lundbeck has become the first business to select Discngine’s proprietary 3decision® collaborative platform to manage its structural knowledge related to protein and ligand 3D structures. The platform, which transforms raw data coming from 3D structures and biomolecular sequences into well-organized and easily accessible knowledge, will be used by Lundbeck to help with the discovery of new treatments for brain diseases.
“We are delighted that Lundbeck has chosen our cloud platform for handling its structural knowledge. This decision shows the increasing importance of collaboration between medicinal and computational chemists,” said Eric Le Roux, founder and CEO of Discngine. “We believe that cloud computing will play an ever increasing role in pharmaceutical research, bringing significant benefits to drug developers and eventually patients.”
“It’s important for us to have instant access to all internal and external structural data, and the 3decision platform is an outstanding tool for our purposes,” said Lena Tagmose, senior director, Molecular Design and Enabling Technologies at Lundbeck. “It’s time-and cost-efficient and brings significant advantages through instant accessibility and a wide range of data modelling options.” The development of the platform began three years ago in a co-operation with Abbvie and was launched as a commercial product in 2018. This year it received the BioIT World 2019 Innovative Practices Award.
Digital Edition
LMUK 49.7 Nov 2024
November 2024
News - Research & Events News - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...
View all digital editions
Events
Nov 11 2024 Dusseldorf, Germany
Nov 12 2024 Cologne, Germany
Nov 12 2024 Tel Aviv, Israel
Nov 18 2024 Shanghai, China
Nov 20 2024 Karachi, Pakistan